GI
NVCR icon

Gradient Investments’s NovoCure NVCR Stock Holding History

Gradient Investments’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-71
Closed -$1.22K – 959
2024
Q2 		$1.22K Hold
71
– – ﹤0.01% 1051
2024
Q1 		$1.11K Hold
71
– – ﹤0.01% 892
2023
Q4 		$1.06K Hold
71
– – ﹤0.01% 1405
2023
Q3 		$1.15K Hold
71
– – ﹤0.01% 1324
2023
Q2 		$2.95K Buy
+71
New +$4.41K ﹤0.01% 1067
2022
Q3 		– Sell
-40
Closed -$3K – 1482
2022
Q2 		$3K Buy
+40
New +$3.01K ﹤0.01% 992

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Gradient Investments's NVCR Position: Q3 2024 in Review

Gradient Investments sold out of NovoCure (NVCR) in Q3 2024, closing a stake of 71 shares — an estimated $1.22K sold.

Gradient Investments first reported a position in NVCR in Q2 2022 and held it in 6 quarters. The position peaked at $3K in Q2 2022. 224 funds tracked by Wall St. Rank hold NVCR as of Q3 2024.

  • Gradient Investments reported no remaining NovoCure position as of Q3 2024 after selling out during the quarter.
  • Gradient Investments sold 71 NovoCure shares in Q3 2024, an estimated $1.22K.
  • Gradient Investments first reported a position in NovoCure in Q2 2022 and held it in 6 quarters.
  • Gradient Investments's NovoCure position peaked at $3K in Q2 2022.
  • 224 funds tracked by Wall St. Rank held NovoCure as of Q3 2024.

Based on Gradient Investments's 13F filing for Q3 2024, filed 15 Oct 2024.